Developmental Therapeutics Recent Publications
2024
- Practical utilization of nonlinear spatial encoding: Fast field mapping and FRONSAC-wave.Zhang HZ, Constable RT, Galiana G. Magn Reson Med. 2024 Sep; 2024 Apr 23. PMID: 38651264.
- Burnout and career satisfaction in young neuro-oncology investigators: Results of the Society for Neuro-Oncology Young Investigator Survey.Youssef G, Acquaye-Mallory A, Vera E, Chheda MG, Dunn GP, Moliterno J, O'Brien BJ, Venere M, Yust-Katz S, Lee EQ, Armstrong TS. Neurooncol Pract. 2024 Aug; 2024 Mar 13. PMID: 39006527.
- Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg A, Stein E, Marcucci G, Bystrom RP, Lindsley RC, Chen EC, Ramos J, Stein A, Pullarkat V, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball B, Stahl M. Am J Hematol. 2024 Aug; 2024 May 15. PMID: 38751104.
- Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia.Bewersdorf JP, Patel KK, Shallis RM, Podoltsev NA, Kewan T, Stempel J, Mendez L, Stahl M, Stein EM, Huntington SF, Goshua G, Zeidan AM. Leuk Lymphoma. 2024 Aug; 2024 Apr 22. PMID: 38648559.
- Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics.Gross M, Huber S, Arora S, Ze'evi T, Haider SP, Kucukkaya AS, Iseke S, Kuhn TN, Gebauer B, Michallek F, Dewey M, Vilgrain V, Sartoris R, Ronot M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey JA. Eur Radiol. 2024 Aug; 2024 Jan 13. PMID: 38217704.
- Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.Dzienis M, Cundom J, Fuentes CS, Spreafico A, Nordlinger M, Pastor AV, Alesi E, Neki A, Fung AS, Figueiredo Lima IP, Oppelt P, da Cunha Junior GF, Burtness B, Franke FA, Tseng JE, Joshi A, McCarthy J, Swaby R, Sidi Y, Gumuscu B, Naicker N, de Castro G Jr. J Clin Oncol. 2024 Jul 22; 2024 Jul 22. PMID: 39038265.
- Glutathione synthesis in the mouse liver supports lipid abundance through NRF2 repression.Asantewaa G, Tuttle ET, Ward NP, Kang YP, Kim Y, Kavanagh ME, Girnius N, Chen Y, Rodriguez K, Hecht F, Zocchi M, Smorodintsev-Schiller L, Scales TQ, Taylor K, Alimohammadi F, Duncan RP, Sechrist ZR, Agostini-Vulaj D, Schafer XL, Chang H, Smith ZR, O'Connor TN, Whelan S, Selfors LM, Crowdis J, Gray GK, Bronson RT, Brenner D, Rufini A, Dirksen RT, Hezel AF, Huber AR, Munger J, Cravatt BF, Vasiliou V, Cole CL, DeNicola GM, Harris IS. Nat Commun. 2024 Jul 21; 2024 Jul 21. PMID: 39034312.
- Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making.Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic LJ, Gebauer B, Jaffe A, Duncan J, Madoff DC, Chapiro J. Eur Radiol. 2024 Jul 20; 2024 Jul 20. PMID: 39033181.
- Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.Porta MGD, Garcia-Manero G, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcárcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Pilot R, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Prebet T, Lai Y, Degulys A, Paolini S, Cluzeau T, Fenaux P, Platzbecker U. Lancet Haematol. 2024 Jul 19; 2024 Jul 19. PMID: 39038479.
- PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer.Barlesi F, Cho BC, Goldberg SB, Yoh K, Zimmer Gelatti AC, Mann H, Gopinathan A, Bielecka ZF, Newton M, Aggarwal C. Future Oncol. 2024 Jul 18; 2024 Jul 18. PMID: 39023287.
- Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.Botta GP, Abdelrahim M, Drengler RL, Aushev VN, Esmail A, Laliotis G, Brewer CM, George GV, Abbate SM, Chandana SR, Tejani MA, Malla M, Bansal D, Rivero-Hinojosa S, Spickard E, McCormick N, Cecchini M, Lacy J, Fei N, Kasi PM, Kasi A, Dayyani F, Hanna DL, Sharma S, Malhotra M, Aleshin A, Liu MC, Jurdi A. Oncologist. 2024 Jul 17; 2024 Jul 17. PMID: 39022993.
- Intramolecular Oxyalkylation of Unactivated Alkenes.Xu Z, Airan Y, Tomanik M, Yang AT, Bhak N, Herzon SB. Tetrahedron. 2024 Jul 17; 2024 May 31. PMID: 38911481.
- Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement.Sundaresan VM, Smani S, Rajwa P, Renzulli J, Sprenkle PC, Kim IY, Leapman MS. Urol Oncol. 2024 Jul 16; 2024 Jul 16. PMID: 39019723.
- Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma.Tripathi A, Tangen CM, Plets M, Li X, Tretiakova M, Humphrey PA, Adeniran A, Barata PC, Gulati S, Bergerot CD, Pruthi DK, Thompson IM, Lara PN Jr, Lerner SP, Pal SK, Shuch BM. BJU Int. 2024 Jul 16; 2024 Jul 16. PMID: 39014969.
- Association of Crowd-Sourced Assessment of Technical Skills (CSATS(TM)) and Outcomes of Robotic Assisted Radical Prostatectomy.Rabil MJ, Jalfon M, Heckscher D, Song Z, Li F, Martin T, Sprenkle PC, Hesse D, Kim IY, Leapman MS, Cavallo JA. Urology. 2024 Jul 15; 2024 Jul 15. PMID: 39019332.
- Rh(II)-Catalyzed Enantioselective S-Alkylation of Sulfenamides with Acceptor-Acceptor Diazo Compounds Enables the Synthesis of Sulfoximines Displaying Diverse Functionality.Patel S, Greenwood NS, Mercado BQ, Ellman JA. Org Lett. 2024 Jul 14; 2024 Jul 14. PMID: 39004842.
- Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence.Xie Z, Komrokji RS, Al-Ali N, Regelson A, Geyer S, Patel AA, Saygin C, Zeidan AM, Bewersdorf JP, Mendez LM, Kishtagari A, Zeidner JF, Coombs CC, Madanat YF, Chung SS, Badar T, Foran JM, Desai P, Tsai C, Griffiths EA, Al Malki MM, Amanam I, Lai C, Deeg HJ, Ades L, Arana-Yi C, Osman AE, Dinner SN, Abaza Y, Taylor J, Chandhok NS, Soong D, Brunner AM, Carraway HE, Singh A, Elena C, Ferrari J, Galli A, Pozzi S, Padron E, Patnaik MM, Malcovati L, Savona MR, Al-Kali A. Blood. 2024 Jul 12; 2024 Jul 12. PMID: 38996210.
- Circulating tumor DNA dynamics reveal KRAS G12C mutation heterogeneity and response to treatment with the KRAS G12C inhibitor divarasib in solid tumors.Choi Y, Dharia NV, Jun T, Chang J, Royer-Joo S, Yau KK, Assaf ZJ, Aimi J, Sivakumar S, Montesion M, Sacher A, LoRusso P, Desai J, Schutzman JL, Shi Z. Clin Cancer Res. 2024 Jul 12; 2024 Jul 12. PMID: 38995268.
- A crisis in clinical research.Hong DS, LoRusso P, Sznol M. J Immunother Cancer. 2024 Jul 11; 2024 Jul 11. PMID: 38991727.
- Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review.Nasioudis D, Pashankar FD. Int J Gynecol Cancer. 2024 Jul 11; 2024 Jul 11. PMID: 38991656.
- Prognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma.Shimer S, Allen OS, Yang C, Canavan M, Westvold S, Kim N, Morillo J, Parker T, Wallace N, Smith CB, Adelson KB. J Palliat Med. 2024 Jul 11; 2024 Jul 11. PMID: 38990245.
- Efficient standardization of clinical T(2)-weighted images: Phase-conjugacy e-CAMP with projected gradient descent.Zhang HZ, Elsaid NMH, Sun H, Tagare HD, Galiana G. Magn Reson Med. 2024 Jul 10; 2024 Jul 10. PMID: 38988054.
- Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers.Huseman ED, Lo A, Fedorova O, Elia JL, Gueble SE, Lin K, Sundaram RK, Oh J, Liu J, Menges F, Rees MG, Ronan MM, Roth JA, Batista VS, Crawford JM, Pyle AM, Bindra RS, Herzon SB. J Am Chem Soc. 2024 Jul 10; 2024 May 30. PMID: 38815248.
- Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.McNamara B, Greenman M, Bellone S, Santin LA, Demirkiran C, Mutlu L, Hartwich TMP, Yang-Hartwich Y, Ratner E, Schwartz PE, Santin AD. Gynecol Oncol. 2024 Jul 8; 2024 Jul 8. PMID: 38981151.
- Risk of Pancreatitis After Endoscopic Ultrasound-Guided Fine Needle Aspiration of Pancreatic Cystic Lesions: A Systematic Review and Meta-Analysis.Magahis PT, Chhoda A, Berzin TM, Farrell JJ, Wright DN, Rizvi A, Hanscom M, Carr-Locke DL, Sampath K, Sharaiha RZ, Mahadev S. Am J Gastroenterol. 2024 Jul 5; 2024 Jul 5. PMID: 38976379.
- Enterococcus faecalis-derived adenine enhances enterohaemorrhagic Escherichia coli Type 3 Secretion System-dependent virulence.Martins FH, Rosay T, Rajan A, Carter HE, Turocy T, Mejia A, Crawford JM, Maresso AW, Sperandio V. Nat Microbiol. 2024 Jul 4; 2024 Jul 4. PMID: 38965331.
- Patterns of brain metastases response to immunotherapy with pembrolizumab.Mahajan A, Goldberg SL, Weiss SA, Tran T, Singh K, Joshi K, Aboian MS, Kluger HM, Chiang VL. J Neurooncol. 2024 Jul 4; 2024 Jul 4. PMID: 38963658.
- Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome.Alhajahjeh A, Bewersdorf JP, Bystrom RP, Zeidan AM, Shimony S, Stahl M. Leuk Lymphoma. 2024 Jul 4; 2024 Jul 4. PMID: 38962996.
- Age-related reduction in anxiety and neural encoding of negative emotional memory.Chaudhary S, Zhang S, Chen Y, Dominguez JC, Chao HH, Li CR. Front Aging Neurosci. 2024; 2024 Jul 3. PMID: 39021704.
- A Th17 cell-intrinsic glutathione/mitochondrial-IL-22 axis protects against intestinal inflammation.Bonetti L, Horkova V, Grusdat M, Longworth J, Guerra L, Kurniawan H, Franchina DG, Soriano-Baguet L, Binsfeld C, Verschueren C, Spath S, Ewen A, Koncina E, Gérardy JJ, Kobayashi T, Dostert C, Farinelle S, Härm J, Fan YT, Chen Y, Harris IS, Lang PA, Vasiliou V, Waisman A, Letellier E, Becher B, Mittelbronn M, Brenner D. Cell Metab. 2024 Jul 3; 2024 Jul 3. PMID: 38986617.
- Pancreatic Cancer Surveillance and Survival of High-Risk Individuals.Blackford AL, Canto MI, Dbouk M, Hruban RH, Katona BW, Chak A, Brand RE, Syngal S, Farrell J, Kastrinos F, Stoffel EM, Rustgi A, Klein AP, Kamel I, Fishman E, He J, Burkhart R, Shin EJ, Lennon AM, Goggins M. JAMA Oncol. 2024 Jul 3; 2024 Jul 3. PMID: 38959011.
- Quantitative Measurement of HER2 Expression in Non-Small Cell Lung Cancer With a High-Sensitivity Assay.Liu M, Vathiotis I, Robbins CJ, Chan NNN, Moutafi M, Burela S, Xirou V, Schalper KA, Herbst RS, Syrigos K, Rimm DL. Mod Pathol. 2024 Jul 2; 2024 Jul 2. PMID: 38964502.
- Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A.Gettinger SN, Song Z, Reckamp KL, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Kong XT, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. JCO Precis Oncol. 2024 Jul. PMID: 38986051.
- NAPRT silencing in FH-deficient renal cell carcinoma confers therapeutic vulnerabilities via NAD+ depletion.Noronha KJ, Lucas KN, Paradkar S, Edmonds J, Friedman S, Murray MA, Liu S, Sajed DP, Sachs C, Spurrier J, Raponi M, Liang J, Zeng H, Sundaram RK, Shuch B, Vasquez JC, Bindra RS. Mol Cancer Res. 2024 Jul 1; 2024 Jul 1. PMID: 38949523.
- A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR. Cancer Res Commun. 2024 Jul 1. PMID: 38920407.
- Assessing readiness to use electronic health record data for outcome ascertainment in clinical trials - A case study.Esserman D, Greene EJ, Latham NK, Kane M, Lu C, Peduzzi PN, Gill TM, Ganz DA. Contemp Clin Trials. 2024 Jul; 2024 May 11. PMID: 38740298.
- Sarcomatoid and Rhabdoid Renal Cell Carcinoma: Clinical, Pathologic, and Molecular Genetic Features.Adeniran AJ, Shuch B, Humphrey PA. Am J Surg Pathol. 2024 Jul 1; 2024 May 13. PMID: 38736105.
- Constrained alternating minimization for parameter mapping (CAMP).Elsaid NMH, Dispenza NL, Hu C, Peters DC, Constable RT, Tagare HD, Galiana G. Magn Reson Imaging. 2024 Jul; 2024 Apr 23. PMID: 38657714.
- Validation of a Rule-Based ICD-10-CM Algorithm to Detect Fall Injuries in Medicare Data.Ganz DA, Esserman D, Latham NK, Kane M, Min LC, Gill TM, Reuben DB, Peduzzi P, Greene EJ. J Gerontol A Biol Sci Med Sci. 2024 Jul 1. PMID: 38566617.
- Disparities in race, ethnicity, sex, and age inclusion in pancreatic cancer screening studies: a systematic review and meta-analysis.Silva-Santisteban A, Hernandez Woodbine MJ, Noriega MA, Rabinowitz LG, Grimshaw A, Farrell JJ, Chhoda A, Sawhney MS. Gastrointest Endosc. 2024 Jul; 2024 Mar 1. PMID: 38432492.
- Low-Field, Low-Cost, Point-of-Care Magnetic Resonance Imaging.Samardzija A, Selvaganesan K, Zhang HZ, Sun H, Sun C, Ha Y, Galiana G, Constable RT. Annu Rev Biomed Eng. 2024 Jul; 2024 Jun 20. PMID: 38211326.
- A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer.Verma N, Johung KL, Kortmansky J, Zaheer W, Lacy J, Cecchini M, Stein S, Cheng YC, Lam W, Liu SH, Reddy V, Hochster H, Higgins SA. J Gastrointest Oncol. 2024 Jun 30; 2024 Jun 25. PMID: 38989411.
- Intensive Induction Chemotherapy versus Hypomethylating Agents in Combination with Venetoclax in NPM1-mutant AML.Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Bystrom R, Lindsley RC, Chen EC, Ramos Perez JM, Stein AS, Pullarkat VA, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball BJ, Stahl M. Blood Adv. 2024 Jun 28; 2024 Jun 28. PMID: 38941537.
- Branching in poly(amine-co-ester) polyplexes impacts mRNA transfection.Shin K, Suh HW, Suberi A, Whang CH, Ene M, Grundler J, Grun MK, Saltzman WM. Biomaterials. 2024 Jun 27; 2024 Jun 27. PMID: 38986360.
- Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza AS, Abid MB, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Hu ZH, Wang HL, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini MC. Blood. 2024 Jun 27. PMID: 38635762.
- β-Amino Acids Reduce Ternary Complex Stability and Alter the Translation Elongation Mechanism.Cruz-Navarrete FA, Griffin WC, Chan YC, Martin MI, Alejo JL, Brady RA, Natchiar SK, Knudson IJ, Altman RB, Schepartz A, Miller SJ, Blanchard SC. ACS Cent Sci. 2024 Jun 26; 2024 Jun 4. PMID: 38947208.
- Fe/Thiol Cooperative Hydrogen Atom Transfer Olefin Hydrogenation: Mechanistic Insights That Inform Enantioselective Catalysis.Buzsaki SR, Mason SM, Kattamuri PV, Serviano JMI, Rodriguez DN, Wilson CV, Hood DM, Ellefsen JD, Lu YC, Kan J, West JG, Miller SJ, Holland PL. J Am Chem Soc. 2024 Jun 26; 2024 Jun 14. PMID: 38875703.
- Neutrophils insert elastase into hepatocytes to regulate calcium signaling in alcohol-associated hepatitis.Ogino N, Leite MF, Guerra MT, Kruglov E, Asashima H, Hafler DA, Ito T, Pereira JP, Peiffer BJ, Sun Z, Ehrlich BE, Nathanson MH. J Clin Invest. 2024 Jun 25; 2024 Jun 25. PMID: 38916955.
- The Xenorhabdus nematophila LrhA transcriptional regulator modulates production of γ-keto-N-acyl amides with inhibitory activity against mutualistic host nematode egg hatching.Lam YC, Hamchand R, Mucci NC, Kauffman SJ, Dudkina N, Reagle EV, Casanova-Torres ÁM, DeCuyper J, Chen H, Song D, Thomas MG, Palm NW, Goodrich-Blair H, Crawford JM. Appl Environ Microbiol. 2024 Jun 25; 2024 Jun 25. PMID: 38916293.
- Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER(+)HER2(-) metastatic breast cancer: a phase 1 trial.Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. Nat Med. 2024 Jun 24; 2024 Jun 24. PMID: 38914862.
- Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2.Mutlu L, McNamara B, Bellone S, Manavella DD, Demirkiran C, Greenman M, Verzosa MSZ, Buza N, Hui P, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Santin AD. Clin Exp Metastasis. 2024 Jun 22; 2024 Jun 22. PMID: 38909139.
- Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations.Jayakrishnan R, Kwiatkowski DJ, Rose MG, Nassar AH. Oncologist. 2024 Jun 22; 2024 Jun 22. PMID: 38907669.
- Procoagulant phenotype of virus-infected pericytes is associated with portal thrombosis and intrapulmonary vascular dilations in fatal COVID-19.Cadamuro M, Lasagni A, Radu CM, Calistri A, Pilan M, Valle C, Bonaffini PA, Vitiello A, Toffanin S, Venturin C, Friòn-Herrera Y, Sironi S, Alessio MG, Previtali G, Seghezzi M, Gianatti A, Strazzabosco M, Strain AJ, Campello E, Spiezia L, Palù G, Frigo AC, Tosoni A, Nebuloni M, Parolin C, Sonzogni A, Simioni P, Fabris L. J Hepatol. 2024 Jun 20; 2024 Jun 20. PMID: 38908437.
- Outcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation.Su DG, Rehman S, Wang K, Deng Y, Rose MG, Dosani T, Kunstman JW. J Surg Res. 2024 Jun 20; 2024 Jun 20. PMID: 38905768.
- Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.Cecchini M, Salem RR, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend JP, Cai G, Chowdhury S, Yugawa D, Tseng R, Mejia Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan SA, Cha C, Billingsley KG, Kunstman JW, Johung KL, Wiess C, Muzumdar MD, Spickard E, Aushev VN, Laliotis G, Jurdi A, Liu MC, Escobar-Hoyos L, Lacy J. JAMA Oncol. 2024 Jun 20; 2024 Jun 20. PMID: 38900452.
- Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy.Diaz GM, Webb LT, Rabil MJ, Lokeshwar SD, Choksi AU, Leapman MS, Sprenkle PC. Curr Urol Rep. 2024 Jun 19; 2024 Jun 19. PMID: 38896314.
- Latrophilin-2 mediates fluid shear stress mechanotransduction at endothelial junctions.Tanaka K, Chen M, Prendergast A, Zhuang Z, Nasiri A, Joshi D, Hintzen J, Chung M, Kumar A, Mani A, Koleske A, Crawford J, Nicoli S, Schwartz MA. EMBO J. 2024 Jun 17; 2024 Jun 17. PMID: 38886581.
- Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine.Zeidan AM, Bewersdorf JP, Hasle V, Shallis RM, Thompson E, de Menezes DL, Rose S, Boss I, Halene S, Haferlach T, Fox BA. Ther Adv Hematol. 2024; 2024 Jun 15. PMID: 38883163.
- Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations.Manrai PA, McHenry A, Sun T, Santin AD, Ratner E, Lin DI, Elvin JA, Hui P, Buza N. Int J Gynecol Pathol. 2024 Jun 10; 2024 Jun 10. PMID: 38914011.
- Bifunctional Molecules That Induce Both Targeted Degradation and Transcytosis of Extracellular Proteins in Brain Cells.Howell RA, Wang S, Khambete M, McDonald DM, Spiegel DA. J Am Chem Soc. 2024 Jun 10; 2024 Jun 10. PMID: 38855935.
- Cost-effectiveness analysis: The missing factor in the management of HCC.Njei B, Yi I, Strazzabosco M. Clin Liver Dis (Hoboken). 2024 Jan-Jun; 2024 Jun 7. PMID: 38860130.
- Copper-Catalyzed Three-Component Synthesis of Highly Substituted Morpholines.Chu D, Zoll AJ, Ellman JA. Org Lett. 2024 Jun 7; 2024 May 29. PMID: 38810982.
- Spatially informed gene signatures for response to immunotherapy in melanoma.Aung TN, Warrell J, Martinez-Morilla S, Gavrielatou N, Vathiotis I, Yaghoobi V, Kluger HM, Gerstein M, Rimm DL. Clin Cancer Res. 2024 Jun 5; 2024 Jun 5. PMID: 38837895.
- Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage.Leapman MS, Ho J, Liu Y, Filson CP, Zhao X, Hakansson A, Proudfoot JA, Davicioni E, Martin DT, An Y, Seibert TM, Lin DW, Spratt DE, Cooperberg MR, Ross AE, Sprenkle PC. JAMA Netw Open. 2024 Jun 3; 2024 Jun 3. PMID: 38874922.
- A small-molecule allele-selective transcriptional inhibitor of the MIF immune susceptibility locus.Li J, Leng L, Pantouris G, Manjula R, Piecychna M, Abriola L, Hu B, Lolis E, Armstrong ME, Donnelly SC, Bucala R. J Biol Chem. 2024 Jun 3; 2024 Jun 3. PMID: 38838773.
- A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol.Neal JW, Minichiello K, Brennick R, Huang RSP, Hiemenz MC, Amler C, Patel J, Herbst R, Reckamp KL, Borghaei H, Highleyman L, Redman MW, Pasquina LW, Kozono DE. Oncologist. 2024 Jun 3. PMID: 38597608.
- Favorable Radiographic Response in a Patient With an Oligodendroglioma Treated With Azacitidine and Venetoclax for Acute Myeloid Leukemia.Perez M, Barrionuevo V, Arias C, Baehring JM. Cureus. 2024 Jun; 2024 Jun 2. PMID: 38957232.
- Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy.Kim IE Jr, Wang AH, Corpuz GS, Sprenkle PC, Leapman MS, Brito JM, Renzulli J, Kim IY. Prostate Int. 2024 Jun; 2024 Feb 7. PMID: 39036758.
- Big Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives.Wang X, Chiang AC. Am Soc Clin Oncol Educ Book. 2024 Jun. PMID: 38830134.
- Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates.Ascione L, Guidi L, Prakash A, Trapani D, LoRusso P, Lou E, Curigliano G. Am Soc Clin Oncol Educ Book. 2024 Jun 1. PMID: 38828973.
- Inhibition of lysine acetyltransferase KAT6 in ER(+)HER2(-) metastatic breast cancer: a phase 1 trial.Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. Nat Med. 2024 Jun 1; 2024 Jun 1. PMID: 38824244.
- Navigating the Complexities of Brain Metastases Management.Amouzegar A, Haig S, Kahn AM, Tawbi HA, Jones JA, Goldberg SB. Am Soc Clin Oncol Educ Book. 2024 Jun. PMID: 38781565.
- Pragmaticism in Cancer Clinical Trials.Sankar K, Redman MW, Dragnev KH, Henick BS, Iams WT, Blanke CD, Herbst RS, Gray JE, Reckamp KL. Am Soc Clin Oncol Educ Book. 2024 Jun. PMID: 38771997.
- Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.Kewan T, Stahl M, Bewersdorf JP, Zeidan AM. Curr Hematol Malig Rep. 2024 Jun. PMID: 38761360.
- Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis.Pasta A, Calabrese F, Jaffe A, Labanca S, Marenco S, Pieri G, Plaz Torres MC, Strazzabosco M, Giannini EG. Liver Cancer. 2024 Jun; 2023 Oct 14. PMID: 38756146.
- Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.Kewan T, Stahl M, Bewersdorf JP, Zeidan AM. Curr Hematol Malig Rep. 2024 Jun; 2024 Apr 18. PMID: 38632155.
- Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.Haumschild R, Kennerly-Shah J, Barbarotta L, Zeidan AM. J Oncol Pharm Pract. 2024 Jun; 2024 Mar 21. PMID: 38509812.
- Ligand-gated ion channels as potential biomarkers for ADT-mediated cognitive decline in prostate cancer patients.Verma S, Singh V, Nagampalli V, Ponsky LE, Li CR, Chao H, Gupta S. Mol Carcinog. 2024 Jun; 2024 Mar 14. PMID: 38482990.
- Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment.Butt A, Christian J, Kress A, Lu BY, Hurwitz ME, Goldberg SB, Podoltsev NA, Gilkes L, Lee AI. J Cancer Educ. 2024 Jun; 2024 Mar 2. PMID: 38430454.
- Multiplexable and Scalable Aqueous Synthesis Platform for Oleate-Based, Bilayer-Coated Gold Nanoparticles.Backhaus A, Albrecht J, Alzhanova G, Long A, Arnold W, Lee J, Tse HY, Su TT, Cruz-Gomez S, Lee SSS, Menges F, Parent LR, Ratjen L, Burtness B, Fortner JD, Zimmerman JB. Small. 2024 Jun; 2024 Feb 20. PMID: 38377304.
- Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.Roussos Torres ET, Ho WJ, Danilova L, Tandurella JA, Leatherman J, Rafie C, Wang C, Brufsky A, LoRusso P, Chung V, Yuan Y, Downs M, O'Connor A, Shin SM, Hernandez A, Engle EL, Piekarz R, Streicher H, Talebi Z, Rudek MA, Zhu Q, Anders RA, Cimino-Mathews A, Fertig EJ, Jaffee EM, Stearns V, Connolly RM. Nat Cancer. 2024 Jun; 2024 Feb 14. PMID: 38355777.
- Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. J Thorac Oncol. 2024 Jun; 2024 Jan 24. PMID: 38278303.
- Prognostic impact of 'multi-hit' versus 'single hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.Badar T, Nanaa A, Atallah E, Shallis RM, Craver EC, Li Z, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, Duvall A, Burkart M, Bradshaw D, Abaza Y, Stahl M, Palmisiano N, Murthy GSG, Zeidan AM, Kota V, Patnaik MM, Litzow MR. Haematologica. 2024 May 30; 2024 May 30. PMID: 38813716.
- A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.Wei W, Blaha O, Esserman D, Zelterman D, Kane M, Liu R, Lin J. Stat Med. 2024 May 30; 2024 Apr 9. PMID: 38594809.
- Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials.Montesinos P, Fathi AT, de Botton S, Stein EM, Zeidan AM, Zhu Y, Prebet T, Vigil CE, Bluemmert I, Yu X, DiNardo CD. Blood Adv. 2024 May 28. PMID: 38507688.
- Scaffold-Oriented Asymmetric Catalysis: Conformational Modulation of Transition State Multivalency during a Catalyst-Controlled Assembly of a Pharmaceutically Relevant Atropisomer.Tampellini N, Mercado BQ, Miller SJ. Chemistry. 2024 May 28; 2024 Apr 11. PMID: 38507249.
- ZFYVE21 promotes endothelial nitric oxide signaling and vascular barrier function in the kidney during aging.Jiang Q, Song G, He L, Li X, Jiang B, Wang Q, Wang S, Kim C, Barkestani MN, Lopez R, Fan M, Wanniarachchi K, Quaranta M, Tian X, Mani A, Gonzalez A, Goodwin JE, Sessa WC, Ishibe S, Jane-Wit D. Kidney Int. 2024 May 24; 2024 May 24. PMID: 38797325.
- Author Correction: Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients.Uhlig J, Uhlig A, Deshpande H, Ströbel P, Trojan L, Lotz J, Hurwitz M, Hafez O, Humphrey P, Grünwald V, Kim HS. Sci Rep. 2024 May 24; 2024 May 24. PMID: 38789511.
- Combining anti-VEGFR and anti-EGFR antibodies: Randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer:(ECOG-ACRIN E7208).Hochster HS, Catalano P, Weitz M, Mitchell EP, Cohen D, O'Dwyer PJ, Faller BA, Kortmanky JS, O'Hara MH, Kricher SM, Lacy J, Lenz HJ, Verma U, Benson AB. J Natl Cancer Inst. 2024 May 22; 2024 May 22. PMID: 38775718.
- Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).Efficace F, Buckstein R, Abel GA, Giesinger JM, Fenaux P, Bewersdorf JP, Brunner AM, Bejar R, Borate U, DeZern AE, Greenberg P, Roboz GJ, Savona MR, Sparano F, Boultwood J, Komrokji R, Sallman DA, Xie Z, Sanz G, Carraway HE, Taylor J, Nimer SD, Della Porta MG, Santini V, Stahl M, Platzbecker U, Sekeres MA, Zeidan AM. Hemasphere. 2024 May; 2024 May 21. PMID: 38774655.
- Entering the golden age for antibody-drug conjugates in gynecologic cancer.Greenman M, McNamara B, Mutlu L, Santin AD. Oncoscience. 2024; 2024 May 20. PMID: 38770444.
- Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, Goff L, Gupta S, Guy J, Hoang HT, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Kortmansky J, Leaf A, Remak WM, Sohal DPS, Taddei TH, Wilson Woods A, Yarchoan M, Rose MG. J Clin Oncol. 2024 May 20; 2024 Mar 19. PMID: 38502889.
- Enhancing in vivo cell and tissue targeting by modulation of polymer nanoparticles and macrophage decoys.Piotrowski-Daspit AS, Bracaglia LG, Eaton DA, Richfield O, Binns TC, Albert C, Gould J, Mortlock RD, Egan ME, Pober JS, Saltzman WM. Nat Commun. 2024 May 18; 2024 May 18. PMID: 38762483.
- Hepatotoxicity assessment of innovative nutritional supplements based on olive-oil formulations enriched with natural antioxidants.Prodromou SI, Chatzopoulou F, Saiti A, Giannopoulos-Dimitriou A, Koudoura LA, Pantazaki AA, Chatzidimitriou D, Vasiliou V, Vizirianakis IS. Front Nutr. 2024; 2024 May 15. PMID: 38812942.
- CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.Segal NH, Melero I, Moreno V, Steeghs N, Marabelle A, Rohrberg K, Rodriguez-Ruiz ME, Eder JP, Eng C, Manji GA, Waterkamp D, Leutgeb B, Bouseida S, Flinn N, Das Thakur M, Elze MC, Koeppen H, Jamois C, Martin-Facklam M, Lieu CH, Calvo E, Paz-Ares L, Tabernero J, Argilés G. Nat Commun. 2024 May 15; 2024 May 15. PMID: 38750034.
- Modifying the Backbone Chemistry of PEG-Based Bottlebrush Block Copolymers for the Formation of Long-Circulating Nanoparticles.Grundler J, Whang CH, Shin K, Savan NA, Zhong M, Saltzman WM. Adv Healthc Mater. 2024 May 11; 2024 May 11. PMID: 38734871.
- Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.Tentori CA, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S, Caballero Berrocal JC, Lanino L, D'Amico S, Spreafico M, Maggioni G, Travaglino E, Sauta E, Meggendorfer M, Zhao LP, Campagna A, Savevski V, Santoro A, Al Ali N, Sallman D, Sole F, Garcia-Manero G, Germing U, Kroger N, Kordasti S, Santini V, Sanz G, Kern W, Platzbecker U, Diez-Campelo M, Maciejewski JP, Ades L, Fenaux P, Haferlach T, Zeidan AM, Castellani G, Komrokji R, Ieva F, Della Porta MG. J Clin Oncol. 2024 May 9; 2024 May 9. PMID: 38723212.
- Approach to immunotherapy for HCC in the liver transplant population.Block PD, Strazzabosco M, Jaffe A. Clin Liver Dis (Hoboken). 2024 Jan-Jun; 2024 May 3. PMID: 38707244.
- Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.Demirkiran C, Greenman M, Bellone S, McNamara B, Hartwich TMP, Manavella D, Mutlu L, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz PE, Coma S, Pachter J, Santin AD. Gynecol Oncol. 2024 May 3; 2024 May 3. PMID: 38703673.
- The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy.Lokeshwar SD, Ali A, Weiss TR, Reynolds J, Shuch BM, Ferencz T, Kyriakides TC, Mehal WZ, Brito J, Renzulli J, Leapman MS. BMC Urol. 2024 May 3; 2024 May 3. PMID: 38702664.